Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  GeNeuro    GNRO   CH0308403085

GENEURO (GNRO)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 07/16 03:23:08 pm
6.16 EUR   --.--%
05/24GENEURO : Proxy Statments
CO
05/24GENEURO : Press Release
CO
05/09GENEURO : 1st quarter earnings
CO
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
07/10/2018 07/11/2018 07/12/2018 07/13/2018 07/16/2018 Date
6.14(c) 6.18(c) 6.14(c) 6.16(c) 6.16(c) Last
1 751 481 1 553 1 096 293 Volume
-0.32% +0.65% -0.65% +0.33% 0.00% Change
More quotes
Financials (EUR)
Sales 2018 8,00 M
EBIT 2018 -10,3 M
Net income 2018 -9,80 M
Finance 2018 13,2 M
Yield 2018 -
Sales 2019 11,7 M
EBIT 2019 -10,1 M
Net income 2019 -7,80 M
Finance 2019 4,80 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 9,84x
EV / Sales2019 7,47x
Capitalization 91,9 M
More Financials
Company
GeNeuro SA engages in the research and development of pharmaceutical products.It offers GNbAC1, a therapeutic antibody that targets MSRV-Env.It also offers a drug for multiple sclerosis.The company was founded by Herve Perron, Christophe Merieux, and Jesus Martin-Garcia in 2006 and is headquartered... 
More about the company
Surperformance© ratings of GeNeuro
Trading Rating : Investor Rating :
More Ratings
Latest news on GENEURO
05/24GENEURO : Proxy Statments
CO
05/24GENEURO : Press Release
CO
05/09GENEURO : 1st quarter earnings
CO
03/29GENEURO SA : annual earnings release
03/29GENEURO : and Servier announce successful 12-month results in neuroprotection fo..
AQ
02/24GENEURO : Receives Orphan Drug Designation from the US FDA for GNbAC1 in Chronic..
AQ
2017GENEURO : Registration document
CO
2017GENEURO : reports cash and revenue for Q3 2017
PU
2017GENEURO : Servier and GeNeuro Announce Promising post hoc Analyses of Six Month ..
AQ
2017GENEURO : Servier and Geneuro to present six month results from CHANGE-MS phase ..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
03/26$TSPT : GeNeuro Hits on 12-Month Data Readout; Clear Signs of Neuroprotective.. 
03/23$TSPT https://t.co/1330rfZH3Y: Pay Attention to GeNeuro; Final Phase IIb Resu.. 
02/22GeNeuro : Receives Orphan Drug Designation from the US FDA for GNbAC1 in Chro.. 
02/12GeNeuro : Reports Cash and Revenue at December 31, 2017  
01/10$TSPT GNRO.PA: GeNeuro Enrolls Final Patient in Phase IIa Study of GNbAC1 in .. 
More tweets
Qtime:75
News from SeekingAlpha
05/09GeNeuro reports Q1 results 
02/12GENEURO SA ORD reports Q4 results 
2017GENEURO SA ORD reports Q3 results 
2017GeNeuro (GNRRF) Presents Review Of Phase llb Week-24 Results - Slideshow 
2017GENEURO SA ORD reports 1H results 
Chart GENEURO
Duration : Period :
GeNeuro Technical Analysis Chart | GNRO | CH0308403085 | 4-Traders
Technical analysis trends GENEURO
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 11,5 €
Spread / Average Target 86%
EPS Revisions
Managers
NameTitle
Jesús Martin-Garcia Chairman & Chief Executive Officer
François Curtin Chief Operating Officer
Miguel Payro Chief Financial Officer
Hervé Perron Chief Scientific Officer
Robert Glanzman Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GENEURO7.88%108
CELLTRION, INC.--.--%31 997
IQVIA HOLDINGS INC9.57%22 131
LONZA GROUP9.72%21 465
INCYTE CORPORATION-25.89%14 878
SEATTLE GENETICS, INC.31.68%11 147